Document Detail


Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy.
MedLine Citation:
PMID:  10609493     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Survival of patients with advanced stage malignant mixed mullerian tumor of the ovary is poor and the best treatment remains unknown. A 62-year-old woman diagnosed with stage IIIC heterologous malignant mixed mullerian tumor of the ovary underwent optimal cytoreductive surgery followed by paclitaxel (135 mg/m2 over 24 hours) and cisplatin (75 mg/m2) every 4 weeks for 6 courses. The patient tolerated chemotherapy well, had complete clinical response and remained without disease for 21 months following diagnosis. Paclitaxel and cisplatin may be effective in malignant mixed mullerian tumors of the ovary.
Authors:
G H Eltabbakh; R Yadav
Related Documents :
12453853 - Phase i/ii study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy ...
12399133 - A phase ii study of non-platinum based chemotherapy with paclitaxel and vinorelbine in ...
21123833 - Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European journal of gynaecological oncology     Volume:  20     ISSN:  0392-2936     ISO Abbreviation:  Eur. J. Gynaecol. Oncol.     Publication Date:  1999  
Date Detail:
Created Date:  2000-01-18     Completed Date:  2000-01-18     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  8100357     Medline TA:  Eur J Gynaecol Oncol     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  355-6     Citation Subset:  IM    
Affiliation:
Division of Gynecolgic Oncology, The University of Vermont, Burlington 05401, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / therapeutic use
Female
Humans
Middle Aged
Mixed Tumor, Mullerian / drug therapy*,  pathology,  surgery
Neoplasm Staging
Ovarian Neoplasms / drug therapy*,  pathology,  surgery
Paclitaxel / therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Internal jugular phlebectasia in children.
Next Document:  The prognostic value of peritoneal cytology in ovarian cancer.